caa a22 4500 463255496 CHVBK 20180405153353.0 cr unu---uuuuu 170326e20070601xx s 000 0 eng 10.1007/s00277-007-0272-z doi (NATIONALLICENCE)springer-10.1007/s00277-007-0272-z Gemtuzumab ozogamicin with cytarabine and mitoxantrone as a third-line treatment in a poor prognosis group of adult acute myeloid leukemia patients: a single-center experience [Elektronische Daten] [G. Specchia, D. Pastore, P. Carluccio, G. Spinosa, M. Giannoccaro, R. Rizzi, A. Mestice, V. Liso] We analyzed the safety and efficacy of gemtuzumab ozogamicin (GO) combined with cytarabine and mitoxantrone in the treatment of 21 patients with acute myeloid leukemia (11 refractory and 10 in second relapse). Patients' median age was 52years (range 36-68); all patients had previously been treated with anthracycline-containing regimens (daunorubicin and idarubicin). GO at a dosage of 3mg/m2 was administered as a 2-h intravenous infusion on days1 and 14, cytarabine at 100mg/m2 on days1-7, and mitoxantrone at 12mg/m2 on days1-3. Infusion-related events were observed in 15 of 21 (71.4%) patients. The incidence of grade 1 or 2 elevations of bilirubin and hepatic transaminases was 4 of 21 (19%) and 3 of 21 (14.2%). In response to chemotherapy, 2 of 21 (9.5%) achieved complete remission and 2 of 21 (9.5%) achieved complete remission with incomplete platelet recovery, with an overall remission rate of 4 of 21(19%); median survival of these 4 patients was 7months. Four of 21 patients (19%) died during aplasia after chemotherapy; no veno-occlusive disease occurred. No treatment-related cardiotoxicity or cerebellar toxicity was observed. In our experience, the addition of GO to mitoxantrone and cytarabine is feasible in refractory or second relapse acute myeloid leukemia patients but yields a low response rate when used as a third-line treatment. Springer-Verlag, 2007 Acute myeloid leukemia nationallicence Refractory nationallicence Relapsed nationallicence Gemtuzumab ozogamicin nationallicence Specchia G. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut Pastore D. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut Carluccio P. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut Spinosa G. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut Giannoccaro M. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut Rizzi R. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut Mestice A. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut Liso V. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut Annals of Hematology Springer-Verlag 86/6(2007-06-01), 425-428 0939-5555 86:6<425 2007 86 277 https://doi.org/10.1007/s00277-007-0272-z text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s00277-007-0272-z text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Specchia G. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut NATIONALLICENCE 700 1- Pastore D. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut NATIONALLICENCE 700 1- Carluccio P. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut NATIONALLICENCE 700 1- Spinosa G. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut NATIONALLICENCE 700 1- Giannoccaro M. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut NATIONALLICENCE 700 1- Rizzi R. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut NATIONALLICENCE 700 1- Mestice A. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut NATIONALLICENCE 700 1- Liso V. Hematology Section, DAP, University of Bari, Piazza G. Cesare 11, 70124, Bari, Italy aut NATIONALLICENCE 773 0- Annals of Hematology Springer-Verlag 86/6(2007-06-01), 425-428 0939-5555 86:6<425 2007 86 277 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer